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Abstract
Background: Neuromyelitis optica (NMO) is an idiopathic, severe, inflammatory demyelinating
disease of the central nervous system, that causes severe optic neuritis and myelitis attacks. Early
discrimination between multiple sclerosis (MS) and NMO is important, as optimum treatment for
both diseases may differ considerably.
Case Presentation: We report a case of a patient who initially presented as longitudinally
extensive transverse myelitis (LETM), having spastic upper extremities diparesis and spastic
paraplegia, C2/C3 sensory level and urinary incontinence, as well as extensive inflammatory spinal
cord lesions from C2 level to conus. After 5 months the patient had another attack of transverse
myelitis, had electrophysiological findings consistent with optic neuritis, was seropositive for NMO-
IgG (aquaporin-4 IgG) and thus fulfilled NMO diagnostic criteria. Following treatment of disease
attacks with pulse corticosteroid therapy and intravenous immunoglobulins, we included oral
azathioprine in a combination with oral prednisone in the therapy. Since there was no significant
clinical improvement, we decided to use cyclophosphamide therapy, which resulted in good clinical
improvement and gradual decrease of cord swelling.
Conclusion: In this NMO case report we wanted to emphasize the extensiveness of inflammatory
spinal cord changes in our patient, from C2 level to conus. In the conclusion it is important to say
that accurate, early diagnosis and distinction from MS is critical to facilitate initiation of
immunosuppressive therapy for attack prevention.
Background
Neuromyelitis optica (NMO) or Devic's syndrome is an
idiopathic, severe, inflammatory demyelinating disease of
the central nervous system that selectively affects optic
nerves and spinal cord. It tends to spare the brain early in
the disease course. Early discrimination between multiple
sclerosis (MS) and NMO is important, as optimum treat-
ment for both diseases may differ considerably. In con-
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suggest that NMO requires long-term immunosuppressive
therapy. Diagnostic criteria for NMO from 1999 have
been revised in 2006 by Wingerchuk et al. Diagnosis
requires absolute criteria and at least two of three support-
ive criteria. Absolute criteria include presence of optic
neuritis and acute myelitis, and supportive criteria nega-
tive brain magnetic resonance imaging (MRI) at disease
onset, spinal cord MRI with contiguous T2-weighted sig-
nal abnormality based centrally in the cord and extending
over 3 or more vertebral segments (LETM - longitudinally
extensive transverse myelitis), and NMO-IgG (aquaporin-
4 IgG) seropositive status [1,2]. NMO-IgG has facilitated
an appreciation that the spectrum of NMO is wider than
previously recognized, and includes patients with recur-
rent longitudinally extensive transverse myelitis, recurrent
isolated optic neuritis, and Japanese opticospinal MS [3].
A variety of encephalopathic presentations may occasion-
ally be encountered in NMO-IgG seropositive patients,
most commonly in children [4].
In this article we report a case of a patient who initially
presented as LETM, having spastic upper extremities
diparesis and spastic paraplegia, C2/C3 sensory level and
urinary incontinence, as well as extensive inflammatory
spinal cord lesions from C2 level to conus. After 5 months
LETM evolved to neuromyelitis optica.
Case Presentation
Patient A.V., Caucasian, born in 1966, with a history of
rhematic fever at the age of 8, in May 2006 was operated
in another institution due to left paramedian L5-S1 disc
herniation, which clinically presented with plegia of the
left leg, pain and hypoesthesia in the left L5 - S1 der-
matome, and urinary incontinence. After operation and
physical rehabilitation her neurological status improved.
However, at the beginning of August 2006, motor weak-
ness of the left leg worsened, and was accompanied by
development of weakness of the right leg. In a few days
she became paraplegic with Th4 sensory level and urinary
incontinence. MRI of the thoracal spinal cord revealed
edematous enlargement extending from Th4 to Th6 level,
suspect of expansive process, but during second operation
5 cm long arachnoid cyst was revealed and neurosurgeons
performed fenestration of the cyst. Soon after she was sent
to physical rehabilitation. In the next few months her con-
dition slightly improved, she again began to walk, with
assistance (crutches). In December 2006 her neurological
status again started to deteriorate, in the next few months
weakness of legs worsened, and she also developed weak-
ness of both arms, accompanied with paresthesiae and
dysesthesiae in arms and legs.
In April 2007 she was admitted to the Department of Neu-
rology of the University Hospital Centre Zagreb. At that
time she had spastic upper extremities diparesis, more
pronounced in the left arm, and spastic paraplegia, with
brisk deep tendon reflexes and bilateral positive Babinski
sign, as well as C2/C3 sensory level and urinary inconti-
nence. MRI revealed T2 hyperintense changes along the
spinal cord from C2 level till conus, with zones of necro-
sis, most prominent in the cervical and cervicothoracal
spinal cord, with widening of central canal in some places
and edematous enlargements. There were few areas of
pathological Gadolinium inhomogenous and ring
enhancement, at C2, C4-C5 and Th1 levels. Those changes
pointed to aggressive inflammatory changes (Figure 1 and
2, April 2007). Brain MRI was normal. In cerebrospinal
fluid (CSF) there were 10 cells/mL (5 lymphocytes and 5
neutrophils), raised total protein level (0.65 g/L), and
positive oligoclonal bands (OCB). Immunological tests
were normal as well as tumor markers, paraneoplastic
antibodies and analysis of serum and CSF for the possible
presence of infectious causes (Borrelia burgdorferi, neuro-
tropic viruses including HIV, Mycobacterium tuberculo-
sis, Treponema pallidum, Mycoplasma pneumoniae).
Visual evoked potentials (VEP) finding was also normal.
We made the diagnosis longitudinal extensive transverse
myelitis (LETM) and started treatment with intravenous
methylprednisolone in a dose of 1000 mg/day for 5 days,
followed by intravenous immunoglobulins (IVIG) in a
dose of 400 mg/kg/day during 5 days, and physical ther-
apy. Slight improvement of her symptoms and regression
of weakness in upper extremities was achieved. Baclofen
and diazepam were also included in the therapy. Control
MRI performed after one month showed decrease of ede-
matous enlargement of the spinal cord. She was sent to
rehabilitation.
After 5 months she again progressively developed weak-
ness, paresthesiae and dysesthesiae in arms, more pro-
nounced in the left arm, as well as transitory blurring of
vision on both eyes. Control MRI of the spinal cord
revealed progression of extensive demyelinating lesions in
the cervical segment. Repeated brain MRI was normal.
Control VEP revealed conduction disturbances (pro-
longed latencies) in both optic pathways. In the mean-
time, we have received positive finding of NMO-IgG
antibodies from Mayo Medical Laboratories. According to
that finding, clinical presentation and MRI finding we
made the diagnosis neuromyelitis optica. Patient was
again treated with intravenous methylprednisolone and
IVIGs, that resulted in minimal clinical improvement of
weakness in upper extremities, but there was no improve-
ment of spastica paraplegia. She remained restricted to
bed. In the following months we also included oral aza-
thioprine in a combination with oral prednisone in the
therapy, but since there was no significant clinical
improvement, we considered other treatment modalities.
In January 2008 we started treatment with intravenousPage 2 of 5
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ylprednisolone (1000 mg), once a month during six
months. Partial remission of disease activity has been
achieved. At the moment patient can use both her arms
and can stand supported by sticks. Her recent MRI of the
spinal cord revealed gradual decrease of cord swelling and
T2 signal hyperintensity. In the meantime, following ster-
oid therapy, she developed diabetes mellitus and oste-
oporosis, that are being treated successfully.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
Discussion
Neuromyelitis optica (NMO) was first identified in the
19th century, as a monophasic, destructive disorder affect-
ing the spinal cord and both optic nerves, but sparing the
remainder of the central nervous system (CNS). The posi-
tion of NMO within the group of CNS demyelinating dis-
eases has been long debated - whether this clinical entity
is a severe variant of MS, a form of acute disseminated
encephalomyelitis, or a distinct disease [5,6]. It has grad-
ually become accepted that the spectrum of idiopathic
NMO is broader than suggested by the historical defini-
tion. The recent discovery of serum autoantibody marker
NMO-IgG in 2004 further advances the hypothesis that
NMO is actually a distinct disease [3]. NMO-IgG is 73%
sensitive and 91% specific for distinguishing NMO from
optic-spinal presentations of classical MS. The target anti-
gen of NMO-IgG is aquaporin 4 (AQP4), glial water chan-
nel protein, that facilitates water transport, especially in
"stress situations" such as brain injury. It is component of
the dystroglycan protein complex located in astrocytic
foot processes at the blood-brain barrier. Data suggest that
autoantibodies to aquaporin 4, derived from peripheral B
cells, cause the activation of complement, inflammatory
demyelination, and necrosis that is seen in neuromyelitis
optica [7,8]. It is also important to emphasize that
patients presenting with a first-ever LETM event, who are
found to be NMO-IgG seropositive, have a 56% risk of
LETM recurrence or optic neuritis (conversion to NMO)
during the subsequent 12 months [9]. With the positive
NMO-IgG finding we confirmed the diagnosis of NMO in
our patient, who satisfied all absolute and supportive
diagnostic criteria [1].
Spinal cord MRI (T2W images) performed in April 2007Figure 1
Spinal cord MRI (T2W images) performed in April 2007. MRI shows extensive T2 hyperintense changes along the spi-
nal cord from C2 level till conus. Those changes were most prominent in the cervical and cervicothoracal spinal cord, with 
widening of central canal in some places and edematous enlargements, as well as with zones of necrosis.Page 3 of 5
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with NMO, perhaps more than 90%, have relapsing rather
than monophasic disease [9], which was also the case in
our patient, but was not recognized as that in the begin-
ning of the disease. Our patient met the features of relaps-
ing NMO, such as female dominance, older age at onset,
and probably autoimmune disease - we could assume that
steroid therapy unmasked autoimmune diabetes mellitus
[10].
For many neurologists, the current standard preventive
approach for NMO includes oral azathioprine in a combi-
nation with oral prednisone, rituximab (chimeric anti-
CD20 monoclonal antibody), mitoxantrone, IVIGs, and
cyclophosphamide [11-17]. The best evidence (although
all from retrospective series) for long-term immunosup-
pression in NMO is with azathioprine and rituximab, that
are considered first line therapies, while cyclophospha-
mide is generally considered as a second line agent in
NMO. In a recently published retrospective multicenter
case series of NMO patients treated with rituximab, that
included 25 patients (including 2 children), 23 of whom
experienced relapses despite use of other drugs before
rituximab, treatment with rituximab appeared to reduce
the frequency of attacks, with subsequent stabilization or
improvement in disability.[14] Jarius et al reported that
treatment with immunosuppressants such as rituximab,
azathioprine and cyclophosphamide resulted in a marked
reduction in antibody levels as well as in relapse rates,
demonstrating a strong relationship between AQP4-Abs
and clinical state. Cyclophosphamide resulted in a long-
lasting relapse-free interval in one of their patients, with
10 relapses within 1295 days (2.82/year) prior to initia-
tion of therapy but only one within 1610 days (0.23/year)
under therapy [15]. Immunoablative cyclophosphamide
was also successful in halting relapses in a patient with
systemic lupus erythematosus-associated NMO who was
unresponsive to high-dose oral and intravenous corticos-
teroids, intravenous immunoglobulin, mycophenolate
mofetil, tacrolimus, low-dose daily oral cyclophospha-
mide and rituximab [17].
After treating diseases attacks with pulse corticosteroid
therapy and IVIGs in our patient, we included oral azathi-
oprine in a combination with oral prednisone in the ther-
apy, but since there was no significant therapeutic
response, we decided to use cyclophosphamide therapy.
That resulted in good clinical improvement and gradual
Spinal cord MRI (T1W images with gadolinium) performed in April 2007Figure 2
Spinal cord MRI (T1W images with gadolinium) performed in April 2007. MRI shows few areas of pathological gado-
linium inhomogenous and ring enhancement, at C2, C4-C5 and Th1 levels. Those changes pointed to aggressive inflammatory 
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decrease in cord swelling and T2 signal hyperintensity. We
were also considering to use rituximab, but at that time
this agent was not approved for treating NMO in Croatia.
It is important to point out that one does not need to wait
for a second attack of transverse myelitis or optic neuritis
prior to commencing immunosuppression if NMO-IgG is
positive, since NMO-IgG itself predicts a relapsing course.
Unfortunately, at the time we received positive finding of
NMO-IgG antibodies from Mayo Clinic, our patient expe-
rienced relapse. If immunosuppresive therapy had been
started earlier in the course of the disease (patient's clini-
cal worsening started to happen one year before admis-
sion to our institution), maybe the prognosis for this
patient could be more favourable.
Conclusion
In this case report we wanted to emphasize the extensive-
ness of inflammatory spinal cord changes in our patient,
from C2 level to conus, which was initially attributed to
LETM, but after some time evolved to neuromyelitis
optica. In the conclusion it is important to say that accu-
rate, early diagnosis and distinction from multiple sclero-
sis is critical to facilitate initiation of immunosuppressive
therapy for attack prevention.
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